RT Journal Article
SR Electronic
T1 RABENOSYN separation-of-function mutations uncouple endosomal recycling from lysosomal degradation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.03.21264281
DO 10.1101/2021.10.03.21264281
A1 Paul, Franziska
A1 Ng, Calista
A1 Nafissi, Shahriar
A1 Nilipoor, Yalda
A1 Tavasoli, Ali Reza
A1 Bonnard, Carine
A1 Wong, Pui-Mun
A1 Nabavizadeh, Nasrinsadat
A1 Estiar, Mehrdad A.
A1 Majoie, Charles B.
A1 Lee, Hane
A1 Nelson, Stanley F.
A1 Gan-Or, Ziv
A1 Rouleau, Guy A.
A1 Van Veldhoven, Paul P.
A1 Massie, Rami
A1 Hennekam, Raoul C.
A1 Kariminejad, Ariana
A1 Reversade, Bruno
YR 2021
UL http://medrxiv.org/content/early/2021/10/05/2021.10.03.21264281.abstract
AB Rabenosyn (RBSN) is a conserved endosomal protein necessary for regulating internalized cargo. Here, we present genetic, cellular and biochemical evidence that two distinct RBSN missense variants are responsible for a novel Mendelian disorder consisting of progressive muscle weakness, facial dysmorphisms, ophthalmoplegia and intellectual disability. Using exome sequencing, we identified recessively-acting germline alleles p.Arg180Gly and p.Gly183Arg which are both situated in the FYVE domain of RBSN. We find that these variants abrogate binding to its cognate substrate PI3P and thus prevent its translocation to early endosomes. Although the endosomal recycling pathway was unaltered, mutant p.Gly183Arg patient fibroblasts exhibit accumulation of cargo tagged for lysosomal degradation. Our results suggest that these variants are separation-of-function alleles, which cause a delay in endosomal maturation without affecting cargo recycling. We conclude that distinct germline mutations in RBSN cause non-overlapping phenotypes with specific and discrete endolysosomal cellular defects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Society in Science Branco Weiss Foundation to B. Reversade, the Strategic Positioning Fund on Genetic Orphan Diseases (GODAFIT) and an Industry Alignment Fund on Singapore Childhood Undiagnosed Diseases Programme (SUREKids) from the Agency for Science, Technology and Research (A*STAR) in Singapore. F. P. is a recipient of long-term EMBO postdoc fellowship and a short-term EMBO travel fellowship as well as a Young Individual Research Grant (YIRG) from the Singapore National Medical Research Council and a Career Development Award (CDA) from A*STAR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A*STAR IRB #2019-087All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author B.R. The data are not publicly available due to restrictions to ensure privacy of research participants.